Swedish Orphan Biovitrum AB (Sobi), founded in 2001 and headquartered in Stockholm, is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare diseases. The company focuses on providing treatments primarily in the hematology, immunology, and genetic disorders sectors, with a portfolio that includes specialty pharmaceuticals and biologics.
| Bond Name | Country | Maturity | Coupon(%) | |||
|---|---|---|---|---|---|---|
| No data found! | ||||||
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Sobi initiated its bond issuance strategy to support its growth and operations in 2015, with significant issuances including a SEK 1 billion bond in 2020, designed to finance acquisitions and general corporate purposes. Current yields on Sobi's bonds are competitive within the biopharmaceutical industry, reflecting investor confidence and sound financial management. Notably, Sobi's bonds feature a fixed interest rate for the entire duration, which appeals to risk-averse investors amid fluctuating market conditions, and the company has maintained a solid credit rating, positioning it well for future growth and additional capital-raising opportunities.